Queen’s spin-out Re-Vana Therapeutics raises €2.9m in funding
Clarendon portfolio company Re-Vana Therapeutics the Queen’s University spin-out has secured $3.25 million (€2.9 million) in funding. Among the backers are three specialised US ophthalmic venture capital funds: ExSight, Visionary and InFocus. Re-Vana is a drug delivery company focused on the treatment of chronic eye diseases such as age-related macular degeneration and Glaucoma. The seed […]
Queen’s spin-out Re-Vana Therapeutics raises €2.9m in funding Read More »